| Code | CSB-RA004888MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to GB-5001, targeting the CD19 antigen expressed on B lymphocytes. CD19 is a transmembrane glycoprotein that serves as a critical B-cell co-receptor, playing an essential role in B-cell development, activation, and antibody production. This surface marker is expressed throughout B-cell differentiation from pre-B cells to plasma cells, making it a defining characteristic of the B-cell lineage. CD19 expression is particularly significant in B-cell malignancies, including B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia, where it serves as both a diagnostic marker and therapeutic target.
As a biosimilar to GB-5001, this antibody provides researchers with a reliable tool for investigating B-cell biology, immune regulation, and lymphoproliferative disorders. It enables studies of B-cell receptor signaling pathways, immune cell phenotyping, and the mechanisms underlying B-cell-mediated diseases. This antibody is particularly valuable for research exploring immunotherapy approaches and understanding B-cell contributions to autoimmune conditions and hematological cancers.
There are currently no reviews for this product.